![]() | Only 14 pages are availabe for public view |
Abstract Peritoneal adhesions are abnormal deposits of fibrin rich matrix on peritoneal surfaces that capable of forming attachment of adjacent viscera. Intraperitoneal peritoneal adhesions are the major source of morbidity, being the commonest cause of intestinal obstruction, secondary female infertility and ectopic gestation. Recombinant human tissue-plasminogen activator (t-PA) has demonstrated beneficial effects on inhibition of peritoneal adhesion; We report herein, to the best of our knowledge, the first use of rt- P A gene therapy loaded on adenovirus vector to prevent adhesion formation and reformation Our study aimed to increase the fibrinolytic capacity In the abdominal cavity for an extended period of time, utilizing an adenoviral vector encoding for t-PA that will infect mesothelial cells of the peritoneum support t-PA overexpression. Therefore, we delivered adenovirus encoding t-PA in the peritoneal cavity to prevent adhesions. In our study, rats were subjected to peritoneal injury and assigned to two protocols; de novo adhesion formation protocol and recurrent adhesion formation protocol. In de novo adhesion formation protocol, recombinant adenoviral vectors expressing wild-type human t-PA gene (Ad-htPA) was instilled after peritoneal injury in group 1 that served as a treated group, whereas group 2 served as a control group and received no vector. In recurrent adhesion formation protocol, group 1 received the same Ad-htP A dose after adhesiolysis and group 2 received served as a control group. Adhesion severity was scored 1 week after ad-htP A instillation. Adhesions were analyzed for human tissue plasminogen activator (ht-PA) |